Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: A prospective cohort

AIDS

Volumn 25, Issue 1, 2011, Pages 87-94

  Omar, Tanvier ^a   Schwartz, Sheree ^b   Hanrahan, Colleen ^b   Modisenyane, Tebogo ^a   Tshabangu, Nkeko ^a   Golub, Jonathan E ^c   McIntyre, James A ^a   Gray, Glenda E ^a   Mohapi, Lerato ^a   Martinson, Neil A ^a,c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antiretroviral therapy; CD4; cervical cancer; cohort; HPV; squamous intraepithelial lesion

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COLPOSCOPY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INCIDENCE; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RISK REDUCTION; SCREENING; SOUTH AFRICA; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; UTERINE CERVIX DYSPLASIA;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; PRECANCEROUS CONDITIONS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SOUTH AFRICA; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 78650304771     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328340fd99     Document Type: Article

References (33)

1. FerlayJ,BrayF, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer-Base No. 5. version 2.0. Lyon: 2004 IARC Press.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55:244-265. (Pubitemid 34293391)
4. Munoz N, Bosch FX, de Sanjose S, Tafur L, Izarzugaza I, Gili M, et al. The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer 1992; 52:743-749.
5. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
6. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186-192.
7. Denny L, Boa R, Williamson AL, Allan B, Hardie D, Stan R, Myer L. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008; 111:1380-1387.
8. Ellerbrock TV, Chiasson MA, Bush TJ, Sun XW, Sawo D, Brudney K, Wright TC Jr. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-1037.
9. Minkoff HL, Eisenberger-Matityahu D, FeldmanJ, Burk R, Clarke L. Prevalence and incidence of gynecologic disorders among women infected with human immunodeficiency virus. Am J Obstet Gynecol 1999; 180:824-836.
10. Cubie HA, Seagar AL, Beattie GJ, Monaghan S, Williams AR. A longitudinal study of HPV detection and cervical pathology in HIV infected women. Sex Transm Infect 2000; 76:257-261.
11. Wright TC Jr, Ellerbrock TV, Chiasson MA, Van Devanter N, Sun XW. Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 1994; 84:591-597.
12. Adam Y, van Gelderen CJ, de Bruyn G, McIntyre JA, Turton DA, Martinson NA. Predictors of persistent cytologic abnormalities after treatment of cervical intraepithelial neoplasia in Soweto, South Africa: a cohort study in a HIV high prevalence population. BMC Cancer 2008; 8:211.
13. Ramos MC, Pizarro De Lorenzo BH, Michelin MA, Murta EF. High-grade cervical intraepithelial neoplasia, human papillo-mavirus and factors connected with recurrence following surgical treatment. Clin Exp Obstet Gynecol 2008; 35:242-247.
14. Mqoqi N, Kellet P, Madhoo J, Sitas F. Incidence of histologically diagnosed cancer in South Africa, 1996-1997. Johannesburg: National Cancer Registry of South Africa, National Health Laboratory Service; 2003.
15. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers? Cape Town: HSRC Press; 2009.
16. Anonymous. South Africa and HIV/AIDS. Setting a better example. Economist 2010; 395:41.
17. Lurie M, Pronyk P, de Moor E, Heyer A, de Bruyn G, Struthers H, et al. Sexual behavior and reproductive health among HIV-infected patients in urban and rural South Africa. J Acquir Immune Defic Syndr 2008; 47:484-493.
18. Golub JE, Pronyk P, Mohapi L, Tshabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
19. Operational plan for comprehensive HIV and AIDS care, management and treatment for South Africa. Department of Health, Republic of South Africa Pretoria; 2003.
20. Solomon D,DaveyD,KurmanR, Moriarty A, O'ConnorD, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2000; 287:2114-2119.
21. Adam Y, van Gelderen CJ, Newell K. 'Look and Lletz': a Chris Hani Baragwanath Hospital experience. S Afr Med J 2008; 98:119-122.
22. Firnhaber C, Van Le H, Pettifor A, Schulze D, Michelow P, Sanne IM, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 2010; 21:433-443.
23. Kiviat N. Natural history of cervical neoplasia: overview and update. Am J Obstet Gynecol 1996; 175:1099-1104.
24. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst 1999; 91:252-258.
25. Miller AB. Natural history of cervical human papillomavirus infections. Lancet 2001; 357:1816.
26. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15:2157-2164.
27. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004; 190:37-45.
28. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, et al. The carcinogenicity of human papilloma-virus types reflects viral evolution. Virology 2005; 337:76-84.
29. Heard I, Schmitz V, Costagliola D, Orth G, Kazatchkine MD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS 1998; 12:1459-1464.
30. Paramsothy P, Jamieson DJ, Heilig CM, Schuman PC, Klein RS, Shah KV, et al. The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009; 113:26-31.
31. Fonn S, Bloch B, Mabina M, Carpenter S, Cronje H, Maise C, et al. Prevalence of precancerous lesions and cervical cancer in South Africa: a multicentre study. S Afr Med J 2002; 92:148-156.
32. The National HIV and syphilis antenatal sero-prevalence survey in South Africa 2007. Department of Health Republic of South Africa, Pretoria 2008.
33. Stanley M. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl 1):S16-S22.